Background: Background:Minimal residual disease (MRD) is a key surrogate for the depth of remission of CLL. The highest rates of undetectable MRD have been observed with regimens using the BH3 mimetic venetoclax. In CLL14, most patients (pts) receiving venetoclax-obinutuzumab (Ven-Obi) had undetectable MRD (uMRD <10 -4 ) at the end of treatment (EoT). However, a subgroup of pts remained MRD positive, regardless of TP53 aberrations or unmutated IGHV status. The biological drivers of response or non-response have so far not been elucidated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.